DEAD-box helicase DP103 defines metastatic potential of human breast cancers.

ABSTRACT: Despite advancement in breast cancer treatment, 30% of patients with early breast cancers experience relapse with distant metastasis. It is a challenge to identify patients at risk for relapse; therefore, the identification of markers and therapeutic targets for metastatic breast cancers is imperative. Here, we identified DP103 as a biomarker and metastasis-driving oncogene in human breast cancers and determined that DP103 elevates matrix metallopeptidase 9 (MMP9) levels, which are associated with metastasis and invasion through activation of NF-?B. In turn, NF-?B signaling positively activated DP103 expression. Furthermore, DP103 enhanced TGF-?-activated kinase-1 (TAK1) phosphorylation of NF-?B-activating I?B kinase 2 (IKK2), leading to increased NF-?B activity. Reduction of DP103 expression in invasive breast cancer cells reduced phosphorylation of IKK2, abrogated NF-?B-mediated MMP9 expression, and impeded metastasis in a murine xenograft model. In breast cancer patient tissues, elevated levels of DP103 correlated with enhanced MMP9, reduced overall survival, and reduced survival after relapse. Together, these data indicate that a positive DP103/NF-?B feedback loop promotes constitutive NF-?B activation in invasive breast cancers and activation of this pathway is linked to cancer progression and the acquisition of chemotherapy resistance. Furthermore, our results suggest that DP103 has potential as a therapeutic target for breast cancer treatment.

SUBMITTER: Shin EM 

PROVIDER: S-EPMC4151228 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature